Comparison study of telmisartan/hydrochlorothiazide tablets and losartan potassium/hydrochlorothiazide tablets on antihypertensive efficacy and reversing vascular endothelial dysfunction

Abstract：Objective To compare the different effects on antihypertensive efficacy and reversing vascular endothelial dys-function (VED) of hypertensive patients by Telmisartan/Hydrochlorothiazide or Losartan Potassium/Hydrochlorothiazide tablets. Methods 61 hypertensive patients were randomly divided into Telmisartan/Hydrochlorothiazide group and Losar-tan Potassium/Hydrochlorothiazide group and received the treatment with Telmisartan/Hydrochlorothiazide tablets or Losartan Potassium/Hydrochlorothiazide tablets 1 tablet per day for 8 weeks. The rates of under control were calculated. Serum hepatocyte growth factor(HGF) ,serum nitric oxide(NO) and plasma endothelin( ET) were measured before and after treatment. Results (1) After 8-week treatment SBP and DBP in either group were significally decreased (P<0.01),but SBP,DBP and the rates of under control were not different between two groups(P>0.05). (2)The levels of serum HGF and plasma ET were higher in hypertensive patients, and the levels of serum NO were lower than those in nor-mal(P<0.01). The levels of serum HGF and plasma ET after treatment were lower group and the levels of serum NO were higher than those before treatment ( P<0.01) , the levels of serum △ HGF and △ NO after treatment were not different between two group (P>0.05) ,but the levels of plasma △ET and △ET/△NO ratio were significally different (P<0.01). Conclusion (1) After 8-week treatment two drugs have the same antihypertensive efficacy. (2) Both drugs have some effects on reversing VED of hypertensive patients, but Telmisartan/hydrochlorothiazide tablets is possiblely better than Losartan potassium/hydrochlorothiazide tablets in reversing VED.